Fast-Tracking Transformative Access to Differentiated Drugs

Returning to Amsterdam on 19–21 May, the 7th Dermatology Drug Development Europe Summit arrives at a defining moment for the field. As dermatology pipelines mature rapidly into Phase II–III, gene therapies reach approval, and immuno-dermatology mechanisms such as JAK, TYK2, IL and OX40 reshape competitive landscapes, the focus has decisively shifted toward not only clinical execution, regulatory readiness, European access, and strengthening translational confidence earlier in development. From improving the predictive value of preclinical skin models and identifying precision biomarkers to overcoming formulation and delivery challenges, the industry is re-evaluating how early decisions shape downstream success. 

What’s new for 2026 is both the depth and breadth of industry representation. This year’s programme brings together a broader range of senior pharma voices than ever before, including Sanofi, Glenmark Pharmaceuticals, Pierre Fabre, Merck and Boehringer Ingelheim, alongside innovative biotechs navigating late-stage development and partnering. Together, they will share candid insights on generating robust clinical signal in high-placebo indications, designing feasible European trials, navigating payer and HTA scrutiny, and translating emerging modalities into approvable, accessible dermatology medicines. 

With 65+ senior clinical, medical, translational and regulatory leaders in an intimate, single-track setting, the Summit is designed for meaningful exchange rather than passive listening, enabling attendees to benchmark strategy across preclinical and clinical development, pressure-test assumptions, and build partnerships that accelerate real-world impact across common and rare dermatological conditions.